skip to main content
UK Health Security Agency

MCF7/LetR-1

MCF7/LetR-1

Catalogue No.

16022524

Cell Line Name

MCF7/LetR-1

Cell Line Description

The MCF7/LetR-1 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors.Letrozole-resistant cell lines were established from MCF-7 cells grown in medium with 10% NCS and 10⁻⁷ M testosterone. A culture of MCF-7 cells were treated with 10-6M letrozole for one week, trypsinized and seeded in serial dilutions in 24-well plates. Single colonies were transferred to new wells and gradually expanded in medium with letrozole. After ~2-3 months, the isolated colonies gave rise to letrozole-resistant cell lines, which could be grown in letrozole-containing medium with a weekly split ratio of ~1:25. This breast cancer cell line resistant to the aromatase inhibitor letrozole. Oestrogen receptor positive. It is progesterone receptor positive when grown in medium without letrozole

General Info

Species

Human

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Receptors

This breast cancer cell line resistant to the aromatase inhibitor letrozole. Oestrogen receptor positive. It is progesterone receptor positive when grown in medium without letrozole

Tissue of Origin

Breast

Morphology

Polygonal epithelia

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 10
D3S1358: 16
D5S818: 11,12
D7S820: 9
D8S1179: 10,14
D13S317: 11
D16S539: 11,12
D18S51: 14
D21S11: 30
FGA: 23,25
Penta D: 12
Penta E: 7,12
TH01: 6
TPOX: 9,12
vWA: 14,15

Applications

The MCF7/LetR-1 Cell Line was developed as a model of resistance to anti-cancer treatment with aromatase inhibitors. Third generation aromatase inhibitors (AIs) have proven to be effective treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of breast cancer patients. However, a major problem is development of resistance against AIs. Since molecular mechanisms of AI resistance are largely undisclosed, the development of cell lines resistant to the non-steroidal AI letrozole allows the study of the molecular basis for resistance to AIs to unravel new targets for treatment

Disease

Carcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10⁴ cells/cm² using 0.05% trypsin or trypsin or trypsin/EDTA; 5% CO₂; 37°C

Culture Medium

Phenol-red-free DMEM/F12 medium supplemented with 10% new born calf serum, 2.5 mM Glutamax, 6 ng/ ml insulin, 0.1 µM testosterone and 1 µM letrozole.

Growth Mode

Adherent

Additional Info

Depositor

Cancer Research Technologies Limited (Ximbio)

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Hole et al. 2015. Breast Cancer Res Treat. 149(3):715-26. PMID: 25667100. Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: MCF7/LetR-1 (ECACC 16022524).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.